386 related articles for article (PubMed ID: 22978848)
1. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
2. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
[TBL] [Abstract][Full Text] [Related]
3. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
Yin R; Cao H; Fu T; Zhang Q; Zhang L; Li L; Gu Z
Rheumatol Int; 2017 Jul; 37(7):1187-1194. PubMed ID: 28551724
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
[TBL] [Abstract][Full Text] [Related]
5. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
[TBL] [Abstract][Full Text] [Related]
6. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
7. Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.
Helget LN; O'Dell JR; Newcomb JA; Androsenko M; Brophy MT; Davis-Karim A; England BR; Ferguson R; Pillinger MH; Neogi T; Palevsky PM; Wu H; Kramer B; Mikuls TR
Arthritis Rheumatol; 2024 Apr; 76(4):638-646. PubMed ID: 37842953
[TBL] [Abstract][Full Text] [Related]
8. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
10. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
[TBL] [Abstract][Full Text] [Related]
11. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
12. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
13. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E
Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
[TBL] [Abstract][Full Text] [Related]
14. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
Timilsina S; Brittan K; O'Dell JR; Brophy M; Davis-Karim A; Henrie AM; Neogi T; Newcomb J; Palevsky PM; Pillinger MH; Pittman D; Taylor TH; Wu H; Mikuls TR
Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007
[TBL] [Abstract][Full Text] [Related]
15. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Dec; 76(12):2065-2070. PubMed ID: 28830881
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Pui K; Gow PJ; Dalbeth N
J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
[TBL] [Abstract][Full Text] [Related]
17. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
Singh JA; Yang S; Saag KG
J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
[TBL] [Abstract][Full Text] [Related]
18. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
[TBL] [Abstract][Full Text] [Related]
19. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
[TBL] [Abstract][Full Text] [Related]
20. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]